TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29627888

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) (1064 nm)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low-Level Laser Therapy (LLLT) (904 nm)
Number of subjects: 70
Study: 28510619

Group type: EXPERIMENTAL
Intervention: Diabetes (9.3% of participants)
Number of subjects: 3069

Group type: COMPARATOR
Intervention: No diabetes (90.7% of participants)
Number of subjects: 3069
Study: 26230432

Group type: EXPERIMENTAL
Intervention: Hydrogymnastics training protocol, performed 5 times a week for 12 weeks, intensity 50-60% of maximum heart rate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 23499637

Group type: EXPERIMENTAL
Intervention: Audiovisual feedback defibrillator (Group 1)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Non-feedback defibrillator (Group 2)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Non-feedback defibrillator (Control group)
Number of subjects: 298
Study: 22069361

Group type: EXPERIMENTAL
Intervention: BDP/F 400/24 μg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: FP/S 500/100 μg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: BDP/F vs FP/S
Number of subjects: 18
Study: 19007693

Group type: EXPERIMENTAL
Intervention: 64-multidetector row coronary computed tomographic angiography (CCTA)
Number of subjects: 230
Study: 16621870

Group type: EXPERIMENTAL
Intervention: Prasugrel 40 mg loading dose (LD) / 5 mg maintenance dose (MD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Prasugrel 40 mg LD / 7.5 mg MD
Number of subjects: 101

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg LD / 75 mg MD
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg MD
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Prasugrel 15 mg MD
Number of subjects: 101
Study: 15286870

Group type: EXPERIMENTAL
Intervention: Racemic bupivacaine 0.75% with epinephrine 1:200.000
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.75% with epinephrine 1:200.000
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 97
Study: 11709686

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Biperiden during radiotherapy and pilocarpine for 6 weeks after
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (neither drug)
Number of subjects: 69
Study: 9212125

Group type: EXPERIMENTAL
Intervention: Microcatheter spinal anesthesia (CSA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined spinal-epidural technique (CSE)
Number of subjects: 60
Study: 7962368

Group type: EXPERIMENTAL
Intervention: Mid-follicular phase
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Late-follicular phase
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Late-follicular phase with abundant cervical mucus
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Endometrial cavity movements
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Endometrial cavity echo‐free space content
Number of subjects: 273
Study: 3069002

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium chloride (Control)
Number of subjects: 20
Study: 31780201

Group type: EXPERIMENTAL
Intervention: Normal A1C (<5.7%)
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Prediabetes (≥5.7 and <6.5%)
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Undiagnosed type 2 diabetes (≥6.5%)
Number of subjects: 1159
Study: 28923465

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) in addition to capillary glucose monitoring
Number of subjects: 325

Group type: COMPARATOR
Intervention: Capillary glucose monitoring alone (Control)
Number of subjects: 325
Study: 25666414

Group type: EXPERIMENTAL
Intervention: Coffee bean polyphenols (CBPs)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (no CBPs)
Number of subjects: 13
Study: 23431369

Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 83
Study: 20665472

Group type: EXPERIMENTAL
Intervention: E. laciniata extract ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 40
Study: 19690439

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17468792

Group type: EXPERIMENTAL
Intervention: Multidisciplinary postoperative rehabilitation programme
Number of subjects: 199

Group type: COMPARATOR
Intervention: Conventional postoperative routines
Number of subjects: 199
Study: 14691426

Group type: EXPERIMENTAL
Intervention: Bicycle ergometer training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Electrical muscle stimulator training
Number of subjects: 46
Study: 11228355

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine without aluminium hydroxide adjuvant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine with aluminium hydroxide adjuvant
Number of subjects: 20

Group type: COMPARATOR
Intervention: 23-valent PS vaccine (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both conjugate vaccines
Number of subjects: 20
Study: 9508168

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MTZ) 8 mg/m2 on days 1, 2, and 3 plus cytarabine (Ara‐C) 100 mg/m2 on days 1 to 7
Number of subjects: 489

Group type: COMPARATOR
Intervention: Daunomycin (DNR) 30 mg/m2 on days 1, 2, and 3 plus cytarabine (Ara‐C) 100 mg/m2 on days 1 to 7
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LD-Ara-C) 10 mg/m2 subcutaneously every 12 hours for 12 days every 6 weeks
Number of subjects: 489

Group type: COMPARATOR
Intervention: No further treatment after initial chemotherapy
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MTZ)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Daunomycin (DNR)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LD-Ara-C)
Number of subjects: 489
Study: 8310991

Group type: EXPERIMENTAL
Intervention: Psyllium seed (10 g/d for 3 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Psyllium husk (10 g/d for 3 weeks)
Number of subjects: 21
Study: 3337484

Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarct extension
Number of subjects: 848

Group type: COMPARATOR
Intervention: Patients without myocardial infarct extension
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Patients with recurrent ischemic pain, previous myocardial infarction, and ST segment depression
Number of subjects: 848

Group type: COMPARATOR
Intervention: Patients without any of the risk factors
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Patients surviving initial hospitalization
Number of subjects: 848
Study: 31054254

Group type: EXPERIMENTAL
Intervention: Group-based CCT (Fit Brains) 3×/week for 1 hour plus 3×/week home-based training
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Group-based CCT preceded by exercise (Ex-CCT) 3×/week for 1 hour plus 3×/week home-based training
Number of subjects: 124

Group type: COMPARATOR
Intervention: Group-based balanced and toned (BAT) classes 3×/week for 1 hour
Number of subjects: 124
Study: 29976469

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy
Number of subjects: 350

Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 350
Study: 27569003

Group type: EXPERIMENTAL
Intervention: Foster care intervention (FCG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Care as usual (CAUG)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Error-related negativity (ERN)
Number of subjects: 12
Study: 26677669

Group type: EXPERIMENTAL
Intervention: Ziyin Huoxue Granule (ZHG) combined with glucocorticoids and antibiotics
Number of subjects: 70

Group type: COMPARATOR
Intervention: Glucocorticoids and antibiotics alone (Control)
Number of subjects: 70
Study: 23580030

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with a transtendon technique (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Arthroscopic full-thickness conversion and repair of the lesion (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 19945276

Group type: EXPERIMENTAL
Intervention: Neurotip
Number of subjects: 44

Group type: COMPARATOR
Intervention: Neuropen
Number of subjects: 44
Study: 17881218

Group type: EXPERIMENTAL
Intervention: Anesthetic intervention during the second stage of labor
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Emergency cesarean delivery
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Presence of anesthesiologist
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Time anesthesiologist present during delivery
Number of subjects: 81
Study: 17164738

Group type: EXPERIMENTAL
Intervention: Subcutaneous preoperative reviparin (4,200 anti Xa IU) once daily
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Unfractionated heparin (7,500 IU) twice daily
Number of subjects: 2018
Study: 12836149

Group type: EXPERIMENTAL
Intervention: Music intervention (soft music without lyrics for 3 hours)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 110
Study: 10712343

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) at 880 microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8857919

Group type: EXPERIMENTAL
Intervention: Autoantibodies against oxidized LDL in NIDDM patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Autoantibodies against oxidized LDL in control subjects
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intimal-medial thickness of the common carotid artery in NIDDM patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intimal-medial thickness of the carotid bifurcation in NIDDM patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cardiovascular events in NIDDM patients
Number of subjects: 91
Study: 1323926

Group type: COMPARATOR
Intervention: Soy phosphatidylcholine (PC) 27 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Soy phosphatidylcholine (PC) 18 g
Number of subjects: 20

Group type: COMPARATOR
Intervention: Safflower oil (SF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soybean oil (SY)
Number of subjects: 20
Study: 6507905

Group type: EXPERIMENTAL
Intervention: Intravenous bupivacaine (2 mg/min for 3 hr)
Number of subjects: 8
Study: 31913560

Group type: EXPERIMENTAL
Intervention: Diabetic neuropathy (DN) defined by neuropathic symptoms and a vibration perception threshold (VPT) ≥ 15 V.
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: High risk for diabetic foot ulceration (DFU) defined by VPT ≥ 25 V.
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Diabetic foot ulceration (DFU).
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Previously undiagnosed diabetic neuropathy (DN).
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Poor glycaemic control (HbA1c ≥ 9%).
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Hyperlipidaemia.
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Hypertension.
Number of subjects: 1082
Study: 29439083

Group type: EXPERIMENTAL
Intervention: Nurse-led preventative psychological intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 26453222

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Solifenacin vs Tamsulosin
Number of subjects: 131
Study: 24854808

Group type: EXPERIMENTAL
Intervention: NOURISH intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 21035214

Group type: EXPERIMENTAL
Intervention: Upstream GP IIb/IIIa inhibitors therapy
Number of subjects: 19469
Study: 20939113

Group type: EXPERIMENTAL
Intervention: EPO1 (30,000 U of Epo before PM and at the end of surgery)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EPO2 (60,000 U of Epo before PM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: STRD (100 mg of hydrocortisone before PM and on postoperative days 1, 2, 3)
Number of subjects: 27
Study: 18522627

Group type: EXPERIMENTAL
Intervention: CS-706 (50 mg oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16108924

Group type: EXPERIMENTAL
Intervention: Functional Incidental Training (FIT) intervention; prompted voiding combined with individualized, functionally oriented endurance and strength‐training exercises offered four times per day, 5 days per week, for 8 weeks
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Functional Incidental Training (FIT) intervention
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (Group 2 before receiving FIT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Functional Independence Measure (FIM) for locomotion and toileting
Number of subjects: 107
Study: 12952110

Group type: EXPERIMENTAL
Intervention: Omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 10372241

Group type: EXPERIMENTAL
Intervention: KJM fiber-enriched test biscuits (0.7 g/412 kJ [100 kcal] of glucomannan)
Number of subjects: 11

Group type: COMPARATOR
Intervention: matched placebo wheat bran fiber biscuits
Number of subjects: 11
Study: 8972416

Group type: COMPARATOR
Intervention: Double gloves
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Single orthopedic gloves
Number of subjects: 341
Study: 1679917

Group type: EXPERIMENTAL
Intervention: Apraclonidine prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 0
Study: 6352606

Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 137

Group type: COMPARATOR
Intervention: cefuroxime
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: mezlocillin and metronidazole
Number of subjects: 137

Group type: COMPARATOR
Intervention: cefuroxime and metronidazole
Number of subjects: 137
Study: 31928474

Group type: EXPERIMENTAL
Intervention: Ground Chia Seed
Number of subjects: 30
Study: 31337877

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: FDG-PET SUVmax ≥10
Number of subjects: 202
Study: 29663901

Group type: EXPERIMENTAL
Intervention: Community-led surveillance and treatment in intervention villages (5 villages, 997 residents)
Number of subjects: 2189

Group type: COMPARATOR
Intervention: Control villages (3 villages, 1,192 residents)
Number of subjects: 2189
Study: 26266647

Group type: EXPERIMENTAL
Intervention: 4-mm buildup
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2-mm buildup
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: No buildup (endocrown)
Number of subjects: 45
Study: 24154863

Group type: EXPERIMENTAL
Intervention: Standard-dose prasugrel (60 mg loading dose / 10 mg daily maintenance dose)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standard-dose prasugrel (10 mg daily maintenance dose)
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-dose clopidogrel (900 mg loading dose / 150 mg daily maintenance dose)
Number of subjects: 42
Study: 23034424

Group type: EXPERIMENTAL
Intervention: Toothbrushing and tongue cleaning with tooth-and-tongue gel
Number of subjects: 54

Group type: COMPARATOR
Intervention: Toothbrushing with reference toothpaste and tongue cleaning
Number of subjects: 54

Group type: COMPARATOR
Intervention: Toothbrushing with reference toothpaste
Number of subjects: 54
Study: 20854964

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (losartan or atenolol)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Normal in-treatment transmitral flow pattern
Number of subjects: 778
Study: 17222276

Group type: EXPERIMENTAL
Intervention: Videotape exposure during delirium tremens
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group without videotape experience
Number of subjects: 60
Study: 15270253

Group type: EXPERIMENTAL
Intervention: qingluo tongbi granules (QTG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Tripterygium glycosides (Control)
Number of subjects: 63
Study: 12495902

Group type: EXPERIMENTAL
Intervention: Peripheral Blood Progenitor Cell (PBPC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bone Marrow (BM)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Patients' spontaneous responses
Number of subjects: 26
Study: 11185631

Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study: 8825366

Group type: EXPERIMENTAL
Intervention: CDCA (chenodeoxycholate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UDCA (ursodeoxycholate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Octreotide alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of CDCA with octreotide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of UDCA with octreotide
Number of subjects: 0
Study: 1479687

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM)
Number of subjects: 49
Study: 3988385

Group type: EXPERIMENTAL
Intervention: Negative expectancy/suggestions for amnesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No expectancy/suggestions for amnesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Negative expectancy/no suggestions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No expectancy/no suggestions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (nonhypnotized)
Number of subjects: 120
Study: 30540701

Group type: EXPERIMENTAL
Intervention: Symptom management interventions
Number of subjects: 495
Study: 30166326

Group type: EXPERIMENTAL
Intervention: RPL554 (6 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ipratropium (40 µg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RPL554 (6 mg) + Ipratropium (40 µg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RPL554 (6 mg) + Salbutamol (200 µg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RPL554 (1.5 or 6 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: RPL554 combined with standard bronchodilators
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 27612991

Group type: EXPERIMENTAL
Intervention: Doxapram dosing adjusted for gender and postmenstrual age (GrA)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Doxapram dosing based on infants' weight alone (GrW)
Number of subjects: 85
Study: 22121008

Group type: COMPARATOR
Intervention: Apical ballooning syndrome (ABS) group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ST-elevation myocardial infarction (STEMI) group
Number of subjects: 12
Study: 22248750

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (HES130/0.4)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lactate Ringer solution (RL)
Number of subjects: 42
Study: 20701510

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/day)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 285
Study: 17432077

Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 139

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 139
Study: 16336059

Group type: EXPERIMENTAL
Intervention: Experimental group received education and a reminder card describing risk factors of CVD.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 160
Study: 11887131

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05 microgram/kg/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meperidine 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 40
Study: 10462387

Group type: EXPERIMENTAL
Intervention: Consensus interferon (9 microg) given three times weekly for 24 weeks
Number of subjects: 420

Group type: COMPARATOR
Intervention: Interferon alfa‐2b (3 million units) given three times weekly for 24 weeks
Number of subjects: 420
Study: 7603929

Group type: EXPERIMENTAL
Intervention: Psychopedagogical intervention programme
Number of subjects: 0
Study: 2195704

Group type: EXPERIMENTAL
Intervention: 6 g Almarin capsules (fish oil concentrate) daily for 12 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Olive oil control
Number of subjects: 111
Study: 29912406

Group type: EXPERIMENTAL
Intervention: glo™ (mentholated or non-mentholated variants)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: iQOS (non-mentholated variant)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Quit nicotine and tobacco product use completely
Number of subjects: 180

Group type: COMPARATOR
Intervention: Combustible cigarettes (control group)
Number of subjects: 180
Study: 28501763

Group type: EXPERIMENTAL
Intervention: six cycles of FEC 100 (Arm A)
Number of subjects: 1515

Group type: COMPARATOR
Intervention: four cycles of FEC 100 (Arm B)
Number of subjects: 1515
Study: 26887213

Group type: EXPERIMENTAL
Intervention: Electro-elongated needle group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual acupuncture group
Number of subjects: 100
Study: 23359185

Group type: EXPERIMENTAL
Intervention: HDC + DC/CIK (120 mg/m(2) docetaxel, 175 mg/m(2) thiotepa, with or without 400 mg/m(2) carboplatin)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard dose chemotherapy (SDC) (75 mg/m(2) docetaxel and 75 mg/m(2) thiotepa)
Number of subjects: 166
Study: 22097348

Group type: EXPERIMENTAL
Intervention: Sanjin tablet
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional sensitive antibiotics
Number of subjects: 68
Study: 19698901

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 615
Study: 16685007

Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg/d
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ciclesonide 1280 microg/d
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ciclesonide treatment groups
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 141